Across
- 1. In a PEA arrest patient with confirmed pulmonary embolism, thrombolytic has only demonstrated benefits if started within this time frame (minutes)
- 5. One of the reversible causes of cardiac arrest to which the only intervention is needle aspiration
- 6. As the result this trial, Lidocaine was added to the 2018 ACLS guidelines as the equivalent alternative to amiodarone for shock-resistance VF/pVT
- 7. During ACLS, this drug should be considered for all hyperkalemic patients
- 12. Maximum off-the-chest time (seconds) during cardiopulmonary resuscitation
- 13. The one "code" drug you should have ready no matter the initial rhythm
- 14. Targeted temperature management has demonstrated survival with favorable neurological outcomes in these patients following achievement of ROSC
- 15. Depth (in inches) of high-quality chest compression
- 16. The drug to consider when encounter a patients with a bradypnea
Down
- 2. Not counting CPR and addressing initial rhythm this step is prioritized even BEFORE administration of epinephrine when resuscitating COVID-19 patients with cardiac arrest
- 3. Maximum cumulative dose (mg) of lidocaine in cardiac arrest
- 4. This should be applied on all patients post-cardiac arrest to rule out STEMI
- 8. The type of outcome that all major epinephrine trials failed to demonstrate benefits
- 9. The only "code" drug that cannot be administered through an endotracheal tube
- 10. Before this RCT, epinephrine never demonstrated improved survival to hospital discharge
- 11. Mean arterial pressor should be maintain over this (mmHg) after achieving ROSC
- 12. Dose of vasopressin when used for IHCA